Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gasherbrum Bio Inc. currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 5 pending office actions indicate an active phase of patent acquisition in the life sciences field. The concentration in Biotechnology & Pharmaceuticals suggests that the company's intellectual property is focused on pharmaceutical or biological developments. Practitioners should note the technical diversity within this technology area.
The 5 pending office actions are distributed across 3 distinct art units and 5 distinct examiners. Because there are 5 distinct examiners for 5 actions, each matter is being reviewed by a unique individual. This distribution across 3 distinct art units shows that the company's technology is recognized across several specialized examination groups at the USPTO. This fragmentation requires careful coordination to ensure consistent arguments across the portfolio.
CHANDRAKUMAR, NIZAL S is the busiest examiner, with 1 busiest examiner pending action. In this portfolio, every one of the 5 distinct examiners is responsible for exactly 1 action, making the workload evenly distributed. Practitioners must manage these 5 pending office actions by engaging with 5 distinct examiners across 3 distinct art units. This requires a broad but coordinated prosecution strategy to handle the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (17%) |
| §112 only | 3 (50%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| BAUER, NICOLA MARIA | 1 | 58.3% | +50.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799609 | HETEROCYCLIC GLP-1 AGONISTS | BAUER, NICOLA MARIA | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248857 | HETEROCYCLIC GLP-1 AGONISTS | BELL, SARA ELIZABETH | 44d overdue |
| 17799609 | HETEROCYCLIC GLP-1 AGONISTS | BAUER, NICOLA MARIA | 30d overdue |
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | CHANDRAKUMAR, NIZAL S | — |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| 1625 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837146 | HETEROCYCLIC GLP-1 AGONISTS | CHANDRAKUMAR, NIZAL S | — | §112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18759609 | HETEROCYCLIC AGONISTS | RAHMANI, NILOOFAR | — | §112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18620978 | SALTS AND SOLID FORMS OF A COMPOUND HAVING GLP-1 AGONIST ACTIVITY | WILLIS, DOUGLAS M | 1624 | §112Other | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18248858 | HETEROCYCLIC GLP-1 AGONISTS | NOLAN, JASON MICHAEL | 1623 | §102 | Non-Final OA | — | Pending | Apr 12, 2023 |
| 18248857 | HETEROCYCLIC GLP-1 AGONISTS | BELL, SARA ELIZABETH | 1625 | §112DP | Final Rejection | 44d overdue | Pending | Apr 12, 2023 |
| 17799609 | HETEROCYCLIC GLP-1 AGONISTS | BAUER, NICOLA MARIA | 1621 | §102§103 | Non-Final OA | 30d overdue | Pending | Aug 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial